Full Library
Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors
Resource type
Journal Article
Authors/contributors
- Ruiz-Camps, Isabel (Author)
- Aguilar-Company, Juan (Author)
Title
Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors
Abstract
This article analyzes the risk of infection associated with small molecule kinase
inhibitors used to treat solid organ malignancies and establishes specific recommendations.
Most of these drugs are orally administered and have the ability to inhibit distinct
kinases, which play a major role in cancer initiation and progression. Although the
true extent of adverse events is not yet known, risk of infection does not seem to
be a major problem with these drugs. Because of the limited clinical experience and
the constant evolution of targeted therapies, recommendations may evolve in the near
future.
Publication
Infectious Disease Clinics
Date
2020/06/01
Volume
34
Issue
2
Pages
257-270
Journal Abbr
Infectious Disease Clinics
Accessed
9/1/21, 3:44 PM
ISSN
0891-5520, 1557-9824
Language
English
Library Catalog
Extra
Publisher: Elsevier
PMID: 32334988
Citation
Ruiz-Camps, I., & Aguilar-Company, J. (2020). Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors. Infectious Disease Clinics, 34(2), 257–270. https://doi.org/10.1016/j.idc.2020.02.005
HEME-ONC AND CELLULAR THERAPIES
Link to this record